Your browser doesn't support javascript.
loading
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Baker, David; Bimali, Milan; Carrillo, Luis; Sachedina, Archana; Alapat, Daisy; Hoque, Md Shadiqul; Kottarathara, Mathew; Parikh, Richa; Erra, Amani; Mitma, Angel A; Mathur, Pankaj; Ogunsesan, Yetunde; Yarlagadda, Lakshmi; Gundarlapalli, Sravani; Thanendrarajan, Sharmilan; Zangari, Maurizio; Van Rhee, Frits; Tricot, Guido; Schinke, Carolina.
Afiliação
  • Baker D; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Bimali M; Arkansas Children's Nutrition Center, Arkansas Children's Hospital, Little Rock, AR; Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock.
  • Carrillo L; Department of Pathology, University of Arkansas for Medical Sciences, Little Rock.
  • Sachedina A; Department of Radiology, University of Arkansas for Medical Sciences, Little Rock.
  • Alapat D; Department of Pathology, University of Arkansas for Medical Sciences, Little Rock.
  • Hoque MS; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Kottarathara M; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Parikh R; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Erra A; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Mitma AA; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Mathur P; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Ogunsesan Y; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Yarlagadda L; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Gundarlapalli S; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Thanendrarajan S; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Zangari M; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Van Rhee F; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Tricot G; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
  • Schinke C; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock. cdschinke@uams.edu.
Haematologica ; 2021 08 12.
Article em En | MEDLINE | ID: mdl-34382384
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article